Tango Therapeutics, Inc.

Form 3 filed by Azelby Robert (Other (specify below) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person Table I - Non-Derivative Securities Beneficially Owned 1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5) Date Exercisable Expiration Date Title Amount or Number of Shares Explanation of Responses: Remarks: Exhibit 24: Power of Attorney No securities are beneficially owned. /s/ Julie Fogarty, as attorney-in-fact 06/23/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. * Form 3: SEC 1473 (03-26)) at TNGX on 2026-06-23. This initial statement of beneficial ownership reports the filer's securities holdings as required under Section 16(a). Filing is routine and indicates an insider's initial ownership disclosure following appointment or acquisition of 10%+ stake.

Delaware 001-39485 85-1195036 reported an officer/director change: intment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 19, 2026, the Board of Directors (the “Board”) of Tango Therapeutics, Inc. (the “Company”) increased the number of directors of the Company to seven (7). Effective June 19, 2026, the Board appointed Robert Azelby as a director of the Company to fill the newly created vacancy on the Board resulting from the increase.

Tango Therapeutics entered into an underwriting agreement on June 9, 2026, with J.P. Morgan and Leerink Partners for an underwritten offering of 18,166,667 shares of common stock and pre-funded warrants to purchase up to 1,833,395 additional shares, all priced at $30.00 per share (or $29.999 for pre-funded warrants). Underwriters received a 30-day option for up to 3,000,009 additional shares. The total offering represents approximately 20 million shares (including pre-funded warrants) raising approximately $600 million gross at $30.00. This is a substantial primary capital raise for a clinical-stage oncology company, highly dilutive but providing significant runway for pipeline advancement.

Tango Therapeutics filed a 424B5 prospectus supplement for an offering of 18,166,667 shares of common stock at $30.00 per share, plus pre-funded warrants for up to 1,833,395 additional shares at $29.999 each (exercise price $0.001), underwritten by J.P. Morgan and Leerink Partners. A 30-day overallotment option covers up to 3,000,009 additional shares at the same price. Total gross proceeds from the base offering are approximately $600 million (shares plus warrants). This is a large dilutive equity raise for a clinical-stage oncology company; the $30.00 pricing relative to the $31.56 prior close suggests modest discount, and the pre-funded warrant structure accommodates certain buyers with ownership concentration constraints.

Tango Therapeutics, Inc. filed a preliminary prospectus supplement (424B5) for an underwritten common stock offering under its existing automatic shelf (Reg. No. 333-291684), with share count, pricing, and total proceeds left blank pending final terms. Joint book-runners are J.P. Morgan, Leerink Partners, Cantor, and Stifel; an overallotment option will be granted. Dilutive equity offering with size TBD — the concurrent 8-K (same date) announcing Phase 1/2 clinical data suggests proceeds will fund ongoing trials.

Tango Therapeutics (TNGX) disclosed initial Phase 1/2 data as of May 28, 2026 for vopimetostat combined with Revolution Medicines' RAS(ON) inhibitors (daraxonrasib and zoldonrasib) in MTAP-deleted/RAS-mutant metastatic pancreatic ductal adenocarcinoma and NSCLC, involving 59 patients across two arms (20 PDAC daraxonrasib, 34 PDAC zoldonrasib, 5 NSCLC daraxonrasib); patients were heavily pretreated with high liver metastasis rates. This is a key clinical catalyst readout — the combination trial in an aggressive tumor type with high unmet need; efficacy details are in the attached press release.

TNGX (TNGX) disclosed the results of its annual meeting of shareholders in an 8-K filing under Item 5.07. Shareholders voted on an advisory say-on-pay resolution, ratification of the independent auditor. All management-sponsored proposals were approved by majority shareholder vote. Annual meeting results are a routine disclosure that confirms shareholder ratification of the board's composition and compensation practices.

TNGX reported period ending 2026-05-13 financial results (8-K Item 2.02). Investors should review the full earnings press release and any management guidance for forward outlook.